InsidersTradesSigma
申报总数
公司
▲ 买入（0 笔）
▼ 卖出（0 笔）
内部人交易记录
首席执行官已披露买入
0
已披露卖出
0
T+90 胜率
0%
T+90 平均收益
-9.5%
基于 2 个已确定 T+90 收益的买入信号。收益基准：公布次日的收盘价。
信号历史
Browse the full record of transactions filed by Caeymaex Emmanuel, 管理人员. Director active across 1 company, notably UCB. Aggregated, 14 reports have been recorded. Activity tracked since 27 August 2025. The latest transaction was disclosed on 8 April 2026 (Sale). Regulator: FSMA. The full history is openly available.
Companies and markets linked to Caeymaex Emmanuel
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报14 总计
7,937 股@ €266.700.0047% mcap29.4% 占其流量ShareEuronext BrusselsISIN BE0003739530FSMA:ucb-33
7,937 股@ €102.040.0018% mcap11.2% 占其流量ShareOff exchangeISIN BE0003739530FSMA:ucb-86
1,010 股@ €271.800.0006% mcap3.8% 占其流量ShareEuronext BrusselsISIN BE0003739530FSMA:ucb-62
4,031 股0Options /warrants for employees or managersOff exchangeFSMA:ucb-129
3,528 股0ShareOff exchangeISIN BE0003739530FSMA:ucb-60
3,000 股@ €254.2710.6% 占其流量ShareEuronext BrusselsISIN BE0003739530FSMA:ucb-198
3,000 股@ €79.993.3% 占其流量ShareOff exchangeISIN BE0003739530FSMA:ucb-187
966 股@ €76.211.0% 占其流量ShareOff exchangeISIN BE0003739530FSMA:ucb-179
966 股@ €238.503.2% 占其流量ShareEuronext BrusselsISIN BE0003739530FSMA:ucb-226
3,000 股@ €79.993.3% 占其流量ShareOff exchangeISIN BE0003739530FSMA:ucb-191
3,000 股@ €238.309.9% 占其流量ShareEuronext BrusselsISIN BE0003739530FSMA:ucb-112
1,500 股@ €248.905.2% 占其流量ShareEuronext BrusselsISIN BE0003739530FSMA:ucb-52
1,500 股@ €247.655.2% 占其流量ShareEuronext BrusselsISIN BE0003739530FSMA:ucb-183
5,000 股@ €200.6813.9% 占其流量ShareEuronext BrusselsISIN BE0003739530FSMA:ucb-128
14 条申报中的 14 条
About Caeymaex Emmanuel
Emmanuel Caeymaex is a senior executive at UCB, a global biopharmaceutical company. In his role, he is responsible for the strategic direction and management of the company's operations. Caeymaex plays a key role in developing innovative solutions for patients, focusing on research and development. His experience in the pharmaceutical industry enables him to contribute effectively to UCB's evolution in the global market.
